Franklin Bivins, MD
Family Medicine · Heber Springs, ARNPI 1427038082
Payments from drug & device makers
Across 143 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$396
- Sanofi-aventis U.S. LLC$221
- Astellas Pharma US Inc$215
- Pfizer$204
- AbbVie$202
- Lilly USA, LLC$155
- plus $972 from 23 others
What the payments were for
- Food & beverage$2,16492%
- Education$2008%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $396 |
| Sanofi-aventis U.S. LLC | 15 | $221 |
| Astellas Pharma US Inc | 3 | $215 |
| Pfizer | 14 | $204 |
| AbbVie(2 entities) | 12 | $202 |
| Lilly USA, LLC | 10 | $155 |
| AstraZeneca | 8 | $123 |
| Abbott | 6 | $120 |
| Novo Nordisk | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| Eisai Inc. | 7 | $91 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Lundbeck LLC | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Boehringer Ingelheim | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Novartis | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,364 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $134,996 |
| EliquisApixaban | 269 | $128,296 |
| OzempicSemaglutide | 99 | $106,283 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $72,356 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $54,644 |
| XareltoRivaroxaban | 44 | $48,668 |
| JanuviaSitagliptin Phosphate | 54 | $44,321 |
| JardianceEmpagliflozin | 69 | $43,873 |
| MounjaroTirzepatide | 21 | $28,826 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $28,438 |
| EntrestoSacubitril/Valsartan | 65 | $24,651 |
| TresibaInsulin Degludec | 58 | $24,628 |
| MyrbetriqMirabegron | 41 | $24,451 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $22,083 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $21,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $396 | $189,878264 claims |
| Novo NordiskOzempic, Tresiba, Levemir, Fiasp | $99 | $147,311207 claims |
| PfizerEliquis, Premarin | $204 | $136,873286 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $123 | $108,767173 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $24 | $57,72196 claims |
| Johnson & JohnsonXarelto | $12 | $48,66844 claims |
| Lilly USA, LLCMounjaro, Trulicity | $155 | $47,60932 claims |
| NovartisEntresto | $11 | $24,65165 claims |
| Astellas Pharma US IncMyrbetriq | $215 | $24,45141 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $54 | $19,64752 claims |
| AbbVieLinzess | $202 | $12,68519 claims |
| Sanofi-aventis U.S. LLCLantus | $221 | $8,94163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Heber Springs
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.